(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 16.24% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Cytosorbents's revenue in 2026 is $37,200,000.On average, 5 Wall Street analysts forecast CTSO's revenue for 2026 to be $2,511,978,304, with the lowest CTSO revenue forecast at $2,406,169,154, and the highest CTSO revenue forecast at $2,595,620,909. On average, 4 Wall Street analysts forecast CTSO's revenue for 2027 to be $3,143,693,469, with the lowest CTSO revenue forecast at $2,899,924,257, and the highest CTSO revenue forecast at $3,365,296,135.
In 2028, CTSO is forecast to generate $3,646,114,248 in revenue, with the lowest revenue forecast at $3,175,090,843 and the highest revenue forecast at $4,104,767,087.